AUTHORS
Alex Francisco Herrera, MD, Dongyun Yang, PhD2, John Baird, MD3, James Godfrey, MD4, Avyakta Kallam, MBBS5, Victor Orellana-Noia, MD6, Tycel Phillips, MD, FASCO7, Christina Poh, MD8, Geoffrey Shouse, DO PhD9, Tanya Siddiqi, MD10, Brian Sworder, MD, PhD11, Ibrahim Aldoss, MD12, Min Guan, MD, PhD13, Saghar Pahlavanneshan, PhD14, Ruby Espinosa15, Sally Mokhtari, PhD16, Elizabeth Nguyen17, Dileshni Tilakawardane18, Lauren Quezada-Urak19, Vanishree Lingegowda Virupakshipura20, Araceli Naranjo21, Jinny Paul22, Jamie Wagner23, Shannon Dempsey24, Corinna La Rosa, PhD25, Sandra Thomas, PhD26, Joycelynne Palmer, PhD27, L. Elizabeth Elizabeth Budde, MD PhD28, Don Diamond, PhD29, Ryotaro Nakamura, MD30, Stephen J. Forman, MD31, Xiuli Wang, PhD32
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States
26 City of Hope, Duarte, California, United States
27 City of Hope, Duarte, California, United States
28 City of Hope, Duarte, California, United States
29 City of Hope, Duarte, California, United States
30 City of Hope, Duarte, California, United States
31 City of Hope, Duarte, California, United States
32 City of Hope, Duarte, California, United States
ABSTRACT
Introduction: CART-cell failure can result from tumor resistance, antigen loss, limited persistence, and exhaustion. To address these barriers, we developed a CMV-specific CD19CART platform in which CD19CAR is transduced into T cells selected for CMV antigen specificity. The platform is designed for in vivo boosting by CMV antigen stimulation with Triplex vaccine, a modified vaccinia Ankara (MVA) virus encoding CMV pp65, IE1, and IE2 antigens. We report preliminary results from 2 pilot feasibility studies in patients (pts) with relapsed/refractory aggressive B-cell lymphoma treated with CMV-CD19CART followed by 2 Triplex doses (IM 5×108 PFU/each) on days 28 and 56 post-CART infusion, either after lymphodepletion (LD, NCT05801913) or autologous (A)HCT (NCT05432635).
Methods: Eligible pts were adults with CMV-seropositive relapsed/refractory aggressive B-cell lymphoma; prior CD19-targeted therapy was allowed. In the LD study, pts had active disease; in the AHCT study, pts were chemosensitive. Each trial included a safety lead-in with CMV-CD19CART cells alone (10x106), followed by CMV-CD19CART cells plus Triplex vaccination. The primary endpoint was safety, including DLT (evaluated after CART infusion and each vaccination). Cellular expansion, cytokine responses, CMV-specific T-cell immunity, and clinical responses were also evaluated.
Results: Eleven pts were enrolled and 9 pts received CMV-CD19CART cells, including 4 in the AHCT study and 5 in the LD study. Median age was 62 years in the AHCT study and 55 years in the LD study. Four pts, 1 AHCT and 3 LD, received 2 Triplex vaccinations. Manufacturing and infusion were successful in 9 of 11 pts. CMVpp65-specific T cell were selected with high purity of IFNγ-positive cells (median 92.4%) after a median expansion of 18 days, with median yield of 95.9×106 cells and median CAR expression of 34.0%.
After initial CART infusion, CAR expansion peaked between days 14 and 28. In Triplex-vaccinated pts, further CART-cell expansion occurred after each vaccination, reaching up to 37.4×103 cells/mL of blood and a 440-fold increase in CAR+ T cells after the 2nd dose, with CMV-CD19CART cells detectable up to 18 months (m) after infusion. No DLTs were observed. Triplex vaccination induced transient increases in inflammatory cytokines, including MCP-1, IL-1RA, GM-CSF, IP-10, and soluble IL-2R, with stronger responses after second vaccination, consistent with immune activation.
Triplex vaccination also expanded functional CMV-specific CD4+ and CD8+ T cells, particularly pp65-specific CD8+ T cells, which reached up to 60×103 cells/mL of blood after the second dose. Levels of CMV-CD19CART and pp65-specific T-cell levels were strongly correlated (p<0.001), supporting vaccine-driven CART-cell re-expansion through CMV antigen-specific immune stimulation.
Cytokine release syndrome (CRS) occurred more often after Triplex vaccination, particularly in the LD pts. In AHCT, 2 of 4 pts developed grade 1 CRS after CMV-CD19CART alone, and 1 vaccinated pt developed grade 2 CRS after the second Triplex dose, resolving without intervention. In LD, 1 of 5 pts developed grade 1 CRS after CMV-CD19CART alone and received tocilizumab. Among 3 vaccinated LD pts, all developed CRS (1 grade 1, 2 grade 3) after the first Triplex dose, and 1 had recurrent grade 3 CRS after the second dose requiring tocilizumab and steroids. Episodes of grade 3 CRS improved to ≤ grade 2 within 72 hours and did not meet DLT criteria.
All 4 AHCT pts achieved CR at 1m post-CD19CART infusion. Two unvaccinated AHCT pts later developed PD at 11m, while 1 unvaccinated and 1 vaccinated pt remain in CR at 2 years and 11m, respectively. In LD, responses 1m after CMV-CD19CART alone included 1 CR, 2 PRs, and 2 SDs. Among 2 unvaccinated LD pts, 1 had initial CR followed by PD at 3m, while the other converted from PR to CR at 3m and remained in CR until allogeneic HCT at 5m. Among 3 vaccinated LD pts, 1 improved from SD to PR after two vaccinations, 1 had PD, and 1 maintained CR after two vaccinations at 4m.
Conclusions: CMV-CD19CART infusions followed by Triplex vaccination were feasible and associated with early evidence of vaccine-driven CART-cell re-expansion, enhanced CMV-specific T-cell immunity, cytokine activation, manageable but clinically meaningful CRS, and objective responses in study pts. The strong correlation between pp65-specific T cells and CMV-specific CART levels supports the intended mechanism of Triplex-mediated CART boosting.
DISCLOSURES
Alex Francisco Herrera, MD: Genentech - Research Funding; Pfizer - Research Funding; BMS - Research Funding; Merck - Research Funding; Merck - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)